Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE
    • Publication Information:
      Publication: 2015->: Abingdon, Oxford : Taylor & Francis
      Original Publication: Orlando, FL : Academic Press, c1993-
    • Subject Terms:
      Micelles*; Antineoplastic Agents/*pharmacokinetics ; Colonic Neoplasms/*drug therapy ; Curcumin/*pharmacokinetics ; Programmed Cell Death 1 Receptor/*antagonists & inhibitors; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents, Immunological ; Cell Line ; Cell Line, Tumor ; Chemistry, Pharmaceutical ; Curcumin/administration & dosage ; Delayed-Action Preparations ; Drug Carriers ; Drug Liberation ; Drug Stability ; Drug Synergism ; Female ; Hemolysis ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Nanoparticles ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Xenograft Model Antitumor Assays
    • Abstract:
      Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a potent anticancer drug with versatile biological activities, while the clinical translation of curcumin is severely limited due to its hydrophobicity, rapid elimination, and metabolism in the blood circulation. Herein, we aim to unravel the potential of curcumin as a synergistic agent with immunotherapy in the treatment of cancers. In an effort to minimize premature release and improve the systemic bioavailability, a superior blood stable and reduction sensitive curcumin micellar formulation, of which the release can be triggered by cancer cells, is rationally designed. We have synthesized a telodendrimer (mPEG-PLA-(LA) 4 ) capable of forming reversible disulfide crosslinked micelles (DCMs). The curcumin loaded DCMs (Cur/DCMs) are spherical with a uniform size of 24.6 nm. The in vitro release profile demonstrates that curcumin releases significantly slower from DCMs than that from non-crosslinked micelles (NCMs), while the release can be accelerated with the increasing concentration of reducing agent glutathione (GSH). Intravenous administration of Cur/DCMs stably retains curcumin in the bloodstream and efficiently improves the systemic bioavailability. Furthermore, Cur/DCMs exhibit synergistic anticancer efficacy when combined with the anti-PD-1 antibody in an MC-38 colon cancer xenograft model. Our results potentiate the integration of blood stable curcumin nanoformulation and immunotherapy for cancer treatment.
    • References:
      Eur J Cancer. 2005 Sep;41(13):1955-68. (PMID: 16081279)
      Langmuir. 2008 May 20;24(10):5213-7. (PMID: 18257595)
      Cancers (Basel). 2020 Aug 04;12(8):. (PMID: 32759757)
      J Am Chem Soc. 2002 Nov 27;124(47):14137-46. (PMID: 12440912)
      Biomaterials. 2009 Apr;30(12):2180-98. (PMID: 19200596)
      Biochem Biophys Res Commun. 1997 Apr 28;233(3):692-6. (PMID: 9168916)
      Int Immunol. 2015 Jan;27(1):39-46. (PMID: 25323844)
      Molecules. 2011 Jun 03;16(6):4567-98. (PMID: 21642934)
      Int J Biochem Cell Biol. 2009 Jan;41(1):40-59. (PMID: 18662800)
      Eur J Cancer. 2013 Sep;49(14):2968-71. (PMID: 23907003)
      Mol Pharm. 2017 Aug 7;14(8):2585-2594. (PMID: 28199114)
      Nano Lett. 2008 Aug;8(8):2180-7. (PMID: 18605701)
      Acta Pharmacol Sin. 2005 Aug;26(8):1009-16. (PMID: 16038636)
      Nanotechnology. 2015 Mar 20;26(11):115101. (PMID: 25708980)
      Carcinogenesis. 1998 Mar;19(3):419-24. (PMID: 9525275)
      Cancer Prev Res (Phila). 2012 Mar;5(3):444-52. (PMID: 22135043)
      Macromol Biosci. 2018 Mar;18(3):. (PMID: 29360270)
      J Med Chem. 2017 Mar 9;60(5):1620-1637. (PMID: 28074653)
      Mol Pharm. 2012 Feb 6;9(2):248-60. (PMID: 22204437)
      Cancer Prev Res (Phila). 2012 Feb;5(2):205-15. (PMID: 22030090)
      Front Pharmacol. 2019 Oct 29;10:1222. (PMID: 31736746)
      Langmuir. 2006 Apr 11;22(8):3570-8. (PMID: 16584228)
      Mol Pharm. 2009 May-Jun;6(3):928-39. (PMID: 19278222)
      Mol Ther. 2016 Feb;24(2):364-374. (PMID: 26334519)
      Biomaterials. 2011 Sep;32(27):6633-45. (PMID: 21658763)
      Clin Cancer Res. 2008 Jul 15;14(14):4491-9. (PMID: 18628464)
      Biomaterials. 2014 Oct;35(30):8635-48. (PMID: 25028336)
      Mol Pharm. 2007 Nov-Dec;4(6):807-18. (PMID: 17999464)
      Biomacromolecules. 2005 Nov-Dec;6(6):3051-6. (PMID: 16283726)
      Front Pharmacol. 2017 Aug 23;8:561. (PMID: 28878676)
      Biochem Pharmacol. 2012 Apr 15;83(8):1104-11. (PMID: 22285912)
      J Biol Chem. 2007 Jun 1;282(22):15954-64. (PMID: 17392282)
      Cancer Chemother Pharmacol. 2011 Jul;68(1):157-64. (PMID: 20859741)
      Br J Cancer. 2004 Mar 8;90(5):1011-5. (PMID: 14997198)
      Cancer Biol Ther. 2007 Feb;6(2):178-84. (PMID: 17218783)
      Chem Commun (Camb). 2008 Dec 28;(48):6570-2. (PMID: 19057782)
      Gut. 2008 Nov;57(11):1509-17. (PMID: 18596194)
      Anticancer Res. 2001 Jul-Aug;21(4B):2895-900. (PMID: 11712783)
      Int Immunopharmacol. 2012 Sep;14(1):99-106. (PMID: 22749847)
      Int J Pept Protein Res. 1990 Aug;36(2):197-200. (PMID: 2272757)
    • Contributed Indexing:
      Keywords: Telodendrimer micelles; bioavailability; cancer immunotherapy; glutathione-triggered release; synergistic effect
    • Accession Number:
      0 (Antineoplastic Agents)
      0 (Antineoplastic Agents, Immunological)
      0 (Delayed-Action Preparations)
      0 (Drug Carriers)
      0 (Micelles)
      0 (Programmed Cell Death 1 Receptor)
      IT942ZTH98 (Curcumin)
    • Publication Date:
      Date Created: 20210512 Date Completed: 20211115 Latest Revision: 20211115
    • Publication Date:
      20240105
    • Accession Number:
      PMC8118404
    • Accession Number:
      10.1080/10717544.2021.1921077
    • Accession Number:
      33975498